By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Drugs > Gilteritinib (systemic) (monograph) > Gilteritinib Dosage
Drugs
https://themeditary.com/dosage-information/gilteritinib-dosage-15609.html

Gilteritinib Dosage

Drug Detail:Gilteritinib (systemic) (monograph) (Xospata)

Drug Class:

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Acute Myeloid Leukemia

120 mg orally once a day until disease progression or unacceptable toxicity

Comments:

  • Response may be delayed. In the absence of disease progression or unacceptable toxicity, patients should be treated for a minimum of 6 months to allow time for a clinical response.
  • Select patients for the treatment of AML with this drug based on the presence of FLT3 mutations in the blood or bone marrow.

Use: For the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3 (FLT3) mutation.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

DOSAGE MODIFICATIONS FOR TOXICITY:
DIFFERENTIATION SYNDROME:

  • If differentiation syndrome is suspected, administer systemic corticosteroids and initiate hemodynamic monitoring until symptom resolution and for a minimum of 3 days.
  • Interrupt therapy if severe symptoms persist for more than 48 hours after initiation of corticosteroids.
  • Resume therapy when symptoms improve to Grade 2 or lower.
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME:
  • Discontinue therapy.
QTc INTERVAL GREATER THAN 500 MSEC:
  • Interrupt therapy; resume therapy at 80 mg orally once a day when QTc interval returns to within 30 msec of baseline or less than or equal to 480 msec.
QTc INTERVAL INCREASED BY MORE THAN 30 MSEC ON ECG ON DAY 8 OF CYCLE 1:
  • Confirm with ECG on Day 9; if confirmed, consider dose reduction to 80 mg orally once a day.
PANCREATITIS: Interrupt therapy until pancreatitis is resolved; resume therapy at 80 mg orally once a day.
OTHER GRADE 3 OR HIGHER TOXICITY CONSIDERED RELATED TO TREATMENT:
  • Interrupt therapy until toxicity resolves to Grade 1; resume therapy at 80 mg orally once a day.

Precautions

US BOXED WARNINGS:

  • Patients treated with this drug have experienced symptoms of differentiation syndrome, which can be fatal if not treated.
  • Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, or renal dysfunction.
  • If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until resolution.
  • If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.

CONTRAINDICATIONS:
  • Hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Do not break or crush tablets.
  • This drug may be taken with or without food.
  • Administer this drug at approximately the same time each day.
  • If a dose is missed or not taken at the usual time, administer it as soon as possible on the same day, and at least 12 hours prior to the next scheduled dose; return to normal schedule the following day.
  • Do not administer 2 doses within 12 hours.

Storage requirements:
  • Store this drug at 20C to 25C (68F to 77F); excursions permitted between 15C to 30C (59F to 86F).
  • Keep in original container.

Monitoring:
  • Assess blood counts and blood chemistries, including creatine phosphokinase, prior to the initiation of therapy, at least once weekly for the first month, once every other week for the second month, and once monthly for the duration of therapy.
  • Perform electrocardiogram (ECG) prior to initiation of therapy, on days 8 and 15 of cycle 1, and prior to the start of the next 2 cycles.

Patient advice:
  • Read the patient information labeling each time you fill this drug.
  • Female patients of reproductive potential should use effective contraceptive methods while receiving therapy and for 6 months after completion.
  • Notify your healthcare provider immediately in the event of a pregnancy or if pregnancy is suspected during therapy.
  • Males with female partners of reproductive potential should use effective contraception during therapy and for at least 4 months after the last dose.
  • Do not breastfeed during therapy and for at least 2 months after.
  • Immediately report a seizure, feeling faint, loss of consciousness, or altered mental status to your healthcare provider.

Frequently asked questions

  • What type of leukemia is Xospata (gilteritinib) used to treat?
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by